| Literature DB >> 24991433 |
Hanne Skarsholm1, Henrik Stoevring2, Bent Nielsen3.
Abstract
Background. Numerous studies have been conducted with a view to developing strategies for improvement of medical compliance in patients with schizophrenia. All of the studies conducted so far have had an individual approach to compliance based on the assumption that noncompliance is determined individually due to inappropriate behavior in the patient. We conducted a pragmatic controlled trial with a system-oriented approach, to provide a new perspective on compliance and test the efficacy of a multifactorial intervention at the system level in a routine clinical setting, an approach that has not previously been used for the improvement of compliance. Methods. 30 patients were allocated to the system-oriented therapy and 40 patients were allocated to the reference intervention, which consisted of individually based compliance therapy. The follow-up period was six months. Primary endpoint was improvement in compliance, measured by improvement in a compliance scale specifically developed for the project. Results. When accounting for missing values with a multiple imputation approach, we found a tendency toward a difference in both the compliance scale and PANSS favoring the system-oriented therapy, although it did not reach statistical significance. A significant difference in incidence of adverse events and time to first readmission was found. Attrition rates were significantly higher in the reference group and nonsignificant among individuals with lower compliance, which may have diluted effect estimates. This was reflected by significant differences found in an analysis based on a last observation carried forward approach. Conclusion. This study suggests that compliance problems are better solved by a multifactorial intervention at the system level than at the individual level.Entities:
Year: 2014 PMID: 24991433 PMCID: PMC4060171 DOI: 10.1155/2014/789403
Source DB: PubMed Journal: Schizophr Res Treatment ISSN: 2090-2093
Figure 1Flow chart.
Baseline demographic and clinical characteristics.
| Individual intervention, | Systemic intervention, |
| |
|---|---|---|---|
| Number | 40 | 30 | |
| Sex (%) | |||
| Male | 17 (42.5) | 14 (46.7) | |
| Female | 23 (57.5) | 16 (53.3) | 0.810 |
| Age, yr (SD) | 43.4 (10.6) | 40.1 (10.0) | 0.195 |
| High school (%) | 19 (47.5) | 12 (40.0) | 0.190 |
| Education (%) | 18 (45) | 15 (50) | 0.810 |
| Livelihood (%) | |||
| Employed | 2 (5.0) | 1 (3.3) | |
| Student | 1 (2.5) | 0 (0.0) | |
| Early retirement (financed by the state) | 35 (87.5) | 26 (86.7) | |
| Cash benefits | 1 (2.5) | 2 (6.7) | |
| Others | 1 (2.5) | 1 (3.3) | 0.949 |
| Crime (%) | |||
| Arrested | 10 (25.0) | 9 (31.0) | 0.597 |
| New diagnosed (%) | 2 (5.0) | 2 (6.7) | 1.000 |
| Number of admissions | 8.5 [2; 31.5] | 10 [1; 50] | 0.384 |
| Duration of illness, yr | 19 [4; 30] | 11 [5; 32] | 0.301 |
| Abuse | |||
| Alcohol and/or drugs | 10 (25.6) | 14 (46.7) | 0.080 |
| Alcohol (+ drugs) | 8 (20.5) | 13 (43.3) | 0.064 |
| Community mental health team | 26 (65.0) | 21 (0.7) | 0.798 |
| Psychosocial functioning (GAF) | 33 [25; 40] | 33 [25; 45] | 0.727 |
| Taking medication | 34 (85.0) | 28 (93.3) | 0.425 |
| Medications | |||
| First-generation drug | 9 (22.5) | 8 (26.7) | 0.781 |
| Second-generation drug | 31 (77.5) | 26 (86.7) | 0.371 |
| Clozapine | 10 (25.0) | 10 (33.3) | 0.594 |
| Depot antipsychotics | 10 (25.0) | 11 (36.7) | 0.307 |
| Polypharmacy | 10 (25.0) | 10 (33.3) | 0.594 |
| Side effects | |||
| Physician assessment | 25 (62.5) | 20 (66.7) | 0.804 |
Missing values: crime 1, number of admissions 1, duration of illness 30, abuse 1, SWN 4, PANSS, all scores 1, remission 1, GAF 2, and side effects 7.
SWN: Subjective Well-Being under Neuroleptic Treatment. PANSS: Positive and Negative Symptom Scale. GAF: Global Assessment of Functioning Scale. Remission: score max 3 on all of the PANSS remission items.
Figure 2Kaplan-Meier survival proportion.
(a) Difference in compliance score from baseline to follow-up, LOCF
| Difference, compliance score mean (CI) |
| |
|---|---|---|
| The individual therapy, | 0.400 (−0.174–0.974) | >0.05 |
| The system-oriented therapy, | 1.103 (0.434–1.733) | <0.05 |
(b) Test on difference between intervention groups
| Coefficient | SE | CI |
| |
|---|---|---|---|---|
| Regression, MI | 0.476 | 0.362 | −0.247–1.120 | 0.193 |
| Regression, LOCF | 0.724 | 0.338 | 0.050–1.398 | 0.036 |